KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Biocryst Pharmaceuticals (BCRX) Cost of Revenue (2016 - 2026)

Biocryst Pharmaceuticals filings provide 14 years of Cost of Revenue readings, the most recent being $9.5 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 56.25% to $9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.1 million, a 55.47% increase, with the full-year FY2025 number at $19.1 million, up 55.47% from a year prior.
  • Cost of Revenue hit $9.5 million in Q4 2025 for Biocryst Pharmaceuticals, up from $2.2 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $9.5 million in Q4 2025 to a low of $236000.0 in Q1 2022.
  • Median Cost of Revenue over the past 5 years was $1.6 million (2023), compared with a mean of $2.5 million.
  • Biggest five-year swings in Cost of Revenue: soared 1166.67% in 2021 and later plummeted 96.02% in 2022.
  • Biocryst Pharmaceuticals' Cost of Revenue stood at $418000.0 in 2021, then skyrocketed by 470.1% to $2.4 million in 2022, then plummeted by 34.66% to $1.6 million in 2023, then surged by 291.39% to $6.1 million in 2024, then surged by 56.25% to $9.5 million in 2025.
  • The last three reported values for Cost of Revenue were $9.5 million (Q4 2025), $2.2 million (Q3 2025), and $2.8 million (Q2 2025) per Business Quant data.